Compare · IART vs RMD
IART vs RMD
Side-by-side comparison of Integra LifeSciences Holdings Corporation (IART) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IART and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.86B, about 19.3x IART ($1.50B).
- Over the past year, IART is up 72.7% and RMD is down 22.9% - IART leads by 95.6 points.
- IART has been more active in the news (9 items in the past 4 weeks vs 7 for RMD).
- Both have 25 recent analyst ratings on file.
- Company
- Integra LifeSciences Holdings Corporation
- ResMed Inc.
- Price
- $19.24-3.15%
- $198.99-1.86%
- Market cap
- $1.50B
- $28.86B
- 1M return
- +8.73%
- +2.60%
- 1Y return
- +72.71%
- -22.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 9
- 7
- Recent ratings
- 25
- 25
Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest IART
- Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
- BMO Capital Markets initiated coverage on Integra with a new price target
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 937 shares, decreasing direct ownership by 3% to 34,516 units (SEC Form 4)
- SEC Form 4 filed by EVP & President, SS Singh Harvinder
- SEC Form 4 filed by EVP & President, TR&DT Davis Robert T. Jr.
- EVP & Chief Financial Officer Knight Lea Daniels covered exercise/tax liability with 5,226 shares, decreasing direct ownership by 10% to 45,263 units (SEC Form 4)
- Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
- Integra LifeSciences Announces Key Executive Appointments
- Integra upgraded by Argus with a new price target
Latest RMD
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)